OBJECTIVE: To evaluate the ability of a preoperative diagnosis of FIGO grade 1 endometrial adenocarcinoma and intraoperative depth of myoinvasion (DOI) to predict low-risk (LR) and high-risk (HR) final uterine pathology. METHODS: We reviewed 1423 consecutive cases of endometrial cancer treated at our institution between 1/1/93 and 5/31/06 to identify cases with a preoperative endometrial biopsy demonstrating FIGO grade 1 endometrial adenocarcinoma. All cases were pathologically reviewed at our institution and underwent surgical therapy at our institution. We excluded equivocal preoperative biopsies as well as those with serous or clear cell histology. Final uterine pathologic findings were grouped into low- and high-risk. Chi-square and Fisher-exact tests were used as appropriate. RESULTS: We identified 490 cases with a median age of 60 years (range 29-90 years). In 482 cases in which final pathologic grade was assessable, FIGO grade was greater in 71 (14.7%) cases; (66 [13.7%] were grade 2, and 5 [1%] were grades 2-3/3). Serous or clear cell histology was diagnosed in 6 (1.2%) additional cases. HR final uterine pathology was seen in 86 (18.5%) cases. Frozen section assessment of DOI, when performed, was associated with HR pathology (p<0.001). HR pathology was present in 3 (3.6%) of 84 cases with either no tumor or myoinvasion identified on frozen section. Lymph node metastasis was identified in 9 (4.4%) of 205 patients that underwent nodal evaluation. CONCLUSIONS: Preoperative FIGO grade 1 diagnosis correlates with final post-hysterectomy grade in 85% of cases. The rate of HR uterine pathology based on preoperative grade 1 alone is 18.5%. Frozen section may help further stratify for the risk of final HR uterine pathology but is not entirely accurate. The rate of HR uterine pathology is 4% if no cancer or myoinvasion is identified on frozen section and 18% if myoinvasion up to 50% is identified.
OBJECTIVE: To evaluate the ability of a preoperative diagnosis of FIGO grade 1 endometrial adenocarcinoma and intraoperative depth of myoinvasion (DOI) to predict low-risk (LR) and high-risk (HR) final uterine pathology. METHODS: We reviewed 1423 consecutive cases of endometrial cancer treated at our institution between 1/1/93 and 5/31/06 to identify cases with a preoperative endometrial biopsy demonstrating FIGO grade 1 endometrial adenocarcinoma. All cases were pathologically reviewed at our institution and underwent surgical therapy at our institution. We excluded equivocal preoperative biopsies as well as those with serous or clear cell histology. Final uterine pathologic findings were grouped into low- and high-risk. Chi-square and Fisher-exact tests were used as appropriate. RESULTS: We identified 490 cases with a median age of 60 years (range 29-90 years). In 482 cases in which final pathologic grade was assessable, FIGO grade was greater in 71 (14.7%) cases; (66 [13.7%] were grade 2, and 5 [1%] were grades 2-3/3). Serous or clear cell histology was diagnosed in 6 (1.2%) additional cases. HR final uterine pathology was seen in 86 (18.5%) cases. Frozen section assessment of DOI, when performed, was associated with HR pathology (p<0.001). HR pathology was present in 3 (3.6%) of 84 cases with either no tumor or myoinvasion identified on frozen section. Lymph node metastasis was identified in 9 (4.4%) of 205 patients that underwent nodal evaluation. CONCLUSIONS: Preoperative FIGO grade 1 diagnosis correlates with final post-hysterectomy grade in 85% of cases. The rate of HR uterine pathology based on preoperative grade 1 alone is 18.5%. Frozen section may help further stratify for the risk of final HR uterine pathology but is not entirely accurate. The rate of HR uterine pathology is 4% if no cancer or myoinvasion is identified on frozen section and 18% if myoinvasion up to 50% is identified.
Authors: Michael R Milam; James Java; Joan L Walker; Daniel S Metzinger; Lynn P Parker; Robert L Coleman Journal: Obstet Gynecol Date: 2012-02 Impact factor: 7.661
Authors: Nadeem R Abu-Rustum; Fady Khoury-Collado; Neeta Pandit-Taskar; Robert A Soslow; Fanny Dao; Yukio Sonoda; Douglas A Levine; Carol L Brown; Dennis S Chi; Richard R Barakat; Mary L Gemignani Journal: Gynecol Oncol Date: 2009-02-20 Impact factor: 5.482
Authors: Jvan Casarin; Francesco Multinu; Nadeem Abu-Rustum; David Cibula; William A Cliby; Fabio Ghezzi; Mario Leitao; Ikuo Konishi; Joo-Hyun Nam; Denis Querleu; Pamela T Soliman; Kathleen J Yost; Amy L Weaver; Andrea Mariani; Gretchen E Glaser Journal: Int J Gynecol Cancer Date: 2019-01 Impact factor: 3.437
Authors: Nicole C M Visser; Johan Bulten; Anneke A M van der Wurff; Erik A Boss; Carolien M Bronkhorst; Harrie W H Feijen; Joke E Haartsen; Hilde A D M van Herk; Ineke M de Kievit; Paul J J M Klinkhamer; Brenda M Pijlman; Marc P M L Snijders; Ingrid Vandenput; M Caroline Vos; Peter E J de Wit; Lonneke V van de Poll-Franse; Leon F A G Massuger; Johanna M A Pijnenborg Journal: BMC Cancer Date: 2015-06-30 Impact factor: 4.430
Authors: Ingvild L Tangen; Reidun K Kopperud; Nicole Cm Visser; Anne C Staff; Solveig Tingulstad; Janusz Marcickiewicz; Frédéric Amant; Line Bjørge; Johanna Ma Pijnenborg; Helga B Salvesen; Henrica Mj Werner; Jone Trovik; Camilla Krakstad Journal: Br J Cancer Date: 2017-07-27 Impact factor: 7.640
Authors: L Helpman; R Kupets; A Covens; R S Saad; M A Khalifa; N Ismiil; Z Ghorab; V Dubé; S Nofech-Mozes Journal: Br J Cancer Date: 2013-12-24 Impact factor: 7.640